Patients experiencing moderate-to-severe plaque psoriasis demonstrated sustained improvements in symptoms, including itching, skin pain, and scaling, over a three-year period when treated with bimekizumab compared to those treated with secukinumab, according to recently published research.
The long-term data, presented in studies published by The New England Journal of Medicine, Medscape Medical News, JAMA Dermatology, and The British Journal of Dermatology, indicate that bimekizumab maintains a higher level of efficacy in addressing key patient-reported outcomes related to quality of life. The studies involved randomized clinical trials, including an open-label extension, assessing both clinical and patient-reported measures.
Bimekizumab, which selectively inhibits interleukin-17A and interleukin-17F, showed greater relief across multiple symptom domains than secukinumab, a medication that targets only interleukin-17A. Researchers evaluated patient-reported outcomes alongside traditional clinical assessments of psoriasis severity.
One study detailed in The New England Journal of Medicine compared the efficacy and safety of the two treatments in patients with moderate-to-severe plaque psoriasis. The research highlighted the differences in how each medication impacted the disease’s symptoms. Further analysis, published in JAMA Dermatology, focused specifically on the patient-reported outcomes over the three-year study duration.
The findings, as reported by Medscape Medical News, suggest that the benefits of bimekizumab are durable, extending up to three years. A report in The British Journal of Dermatology examined the efficacy and safety of bimekizumab in patients receiving continuous treatment or those who switched from secukinumab after one year, reinforcing the sustained positive effects observed in the broader trials.
